Novel insights into the treatment of complement-mediated hemolytic anemias by Sigbjørn Berentsen, Anita Hill, Quentin A. Hill, Tor Henrik Anderson Tvedt, Marc Michel

Get full text

Lower Circulating B12 Is Associated with Higher Obesity and Insulin Resistance during Pregnancy in a Non-Diabetic White British Population. by Bridget Ann Knight, Beverley M Shields, Adam Brook, Anita Hill, Dattatray S Bhat, Andrew T Hattersley, Chittaranjan S Yajnik

Get full text

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. by John Devin Peipert, Austin G Kulasekararaj, Anna Gaya, Saskia M C Langemeijer, Susan Yount, F Ataulfo Gonzalez-Fernandez, Emilio Ojeda Gutierrez, Christa Martens, Amy Sparling, Kimberly A Webster, David Cella, Ioannis Tomazos, Masayo Ogawa, Caroline I Piatek, Richard Wells, Flore Sicre de Fontbrune, Alexander Röth, Lindsay Mitchell, Anita Hill, Karen Kaiser

Get full text

He Said/She Said: Truth-Telling and #MeToo by Leigh Gilmore

“…It historicizes the #MeToo movement within feminist activism in communities of colour around sexual assault advocacy and in relation to Anita Hill's testimony in 1991 that Clarence Thomas sexually harassed her. …”
Get full text

He Said/She Said: Truth-Telling and #MeToo by Leigh Gilmore

“…It historicizes the #MeToo movement within feminist activism in communities of colour around sexual assault advocacy and in relation to Anita Hill's testimony in 1991 that Clarence Thomas sexually harassed her. …”
Get full text

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab by Richard Kelly, Stephen Richards, Peter Hillmen, et al

“…Richard Kelly1, Stephen Richards1, Peter Hillmen1, Anita Hill21Institute of Oncology, St. James’s University Hospital, Leeds, UK; 2Department of Haematology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UKAbstract: Paroxysmal nocturnal hemoglobinuria is a rare disorder of hemopoietic stem cells. …”
Get full text

Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicente... by Shammo J, Gajra A, Patel Y, Tomazos I, Kish J, Hill A, Sierra JR, Araten D

“…Jamile Shammo,1 Ajeet Gajra,2 Yogesh Patel,3 Ioannis Tomazos,3 Jonathan Kish,2 Anita Hill,4 J Rafael Sierra,3 David Araten5 1Rush Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, USA; 2Cardinal Health Inc., Charlotte, NC, USA; 3Alexion, AstraZeneca Rare Disease, Boston, MA, USA; 4Alexion, AstraZeneca Rare Disease, Inc., Leeds, UK; 5Division of Hematology, New York University School of Medicine, New York, NY, USACorrespondence: Jamile Shammo, Email jamile_shammo@rush.eduPurpose: Most patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with a complement protein 5 (C5) inhibitor achieve full control of terminal complement activity and intravascular hemolysis. …”
Get full text